Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
Status:
Completed
Trial end date:
2019-08-03
Target enrollment:
Participant gender:
Summary
This is a pilot, open label single arm phase 0 window of opportunity study of
vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
Phase:
Early Phase 1
Details
Lead Sponsor:
Biocompatibles UK Ltd Boston Scientific Corporation